Slide 1: Transforming Nerve Repair Through Science: Quarterly Update
For personal use only ASX:RNV Transforming Nerve Repair Sales & Through Science Marketing Quarterly Update update ReNerve Board meeting | July 2025 ReNerve Company update | August 2025 1
Slide 2: Important Notice & Disclaimer
Important Notice & Disclaimer Nature of Document: This presentation has been prepared and issued by ReNerve Ltd (Company) to provide general information about the Company. The information in this document is in summary form and should not be relied upon as a complete and accurate representation of a
Slide 3: Executive Summary
Executive Summary Development of Novel Nerve Repair & Regeneration Products For personal use only ReNerve is developing a portfolio of products for the nerve repair and regeneration markets, with clearly defined commercial demand. Expanding Product Portfolio 4 product ranges expected on market by ye
Slide 4: Global Nerve Repair Biomaterial Market
Global Nerve Repair Biomaterial Market ReNerve $8.0Bn $6.0Bn Target For personal use only $4.0Bn USD $Bn Markets $2.0Bn - 2024 2025 2026 2027 2028 2029 2030 2031 North America Europe Asia Pacific Dermal & Amniotic Tissue Sales market in USD$M $2,500.00 $2,000.00 $1,500.00 $1,000.00 $500.00 MarketWid
Slide 5: ReNerve's Nerve Opportunity
ReNerve’s Nerve Opportunity Nerve Cuff Nerve Conduit Nerve Guide Matrix Bionic Nerve For personal use only • Used on damaged or transected • Improved Nerve Cuff developed from • An ‘off-the-shelf’, ready to use nerve • An ‘off-the-shelf’, continuous nerve Product nerves with no gaps or gap closure s
Slide 6: Company Quarterly Highlights
Company Quarterly Highlights For personal use only Sales Highlights ReNerve Key Quarterly activities New product ranges to market • Partnership with Berkeley Biologics for two main • Year on year sales up 53% product ranges • Products already approved • Closing cash of $4.75M • Complement existing t
Slide 7: Distribution Network Expanded
Distribution Network Expanded Distribution Channels Robust portfolio • Expanded to 21 distributors For personal use only across the US • Distributors selling the ReNerve product ranges • Will include additional products as they come to market Focus surgical areas Subspecialties • Hand (upper extremi
Slide 8: The Berkeley - ReNerve Product Ranges
The Berkeley - ReNerve Product Ranges Why take on these products? For personal use only 1| Surgeons using NervAlign 2| They also use dermal and 3| Taking on these products products routinely use dermal amniotic membranes in cases expands ReNerve’s revenue and amniotic membranes in where a nerve repa
Slide 9: Benefits of Amniotic Product Range
Benefits of Amniotic Product Range For personal use only • Used in orthopaedic, plastic and general surgery – especially for chronic wounds and wound closure • Enables rapid, non-pathologic healing and remodelling of surgical and reconstructive wounds • Acts as a natural barrier to protect from exte
Slide 10: Deep-Layer Dermal Product Range
Deep-Layer Dermal Product Range For personal use only • Used in orthopaedic, plastic and general surgery • Provides a scaffold for cell infiltration and organised healing • Scaffold is made from natural bioactive components (collagen, elastin, glycosaminoglycans) • Unlike competitor products, the de
Slide 11: Key Dermal Product Benefits
Key Dermal Product Benefits Unprocessed For personal use only Dermal Tissue DESIGNED AND PROCESSED TO PRESERVE THE NATURAL MATRIX AS CLOSELY AS POSSIBLE TO UNPROCESSED DERMIS FOR OPTIMAL TISSUE REPAIR AND REGENERATION. CLOSEST TO NATURAL DERMAL TISSUE, COMPARED TO OTHER DERMAL PRODUCTS1. New ReNerve
Slide 12: Continued Distributor Engagement and Company Value Drivers for H2 CY25
Continued Distributor Engagement 3 new products ranges into the US market this CY For personal use only • Dermal and amniotic products to market this quarter Company value • • First conduit product by year end Provides sales teams a range of 4 drivers for H2 CY25 product by year end, expected to aid
Slide 13: Near Term Milestones - 2025
Near Term Milestones - 2025 1H 2025 2H 2025 Near Term For personal use only NervAlign® Nerve Conduit into Market 27 February 2025 Progression of the Nerve (Q4 2025/Q1 2026) Partnership Signed for Mexico Market Guide Matrix to Stage 3 of Development 7 March 2025 Initial sales of the dermal and R&D Ta
Slide 14: Investment Highlights
Investment Highlights For personal use only In Market Product Immediate Market Need Growing Market Nerve Cuff transitioned from R&D to Product offering promotes nerve injury Nerve repair biomaterials and related commercial sales post FDA market clearance, recovery and regrowth leading to faster mark
Slide 15: Contact
For personal use only ASX:RNV Contact ReNerve Limited +61 (03) 9482 3940 info@renerve.com.au Level 10/99 Queen St, Melbourne, Victoria 3000 Australia